AMBI 15.60 Ambit Biosciences Corp $AMBI Hit a 52 w
Post# of 94279
Posted On: 11/11/2014 10:22:25 AM
AMBI 15.60 Ambit Biosciences Corp $AMBI Hit a 52 week high of 16.25 Currently at 15.60 +0.26 +1.69% With a day low of 15.40 and a total volume of 140,100.
AMBI Ambit Biosciences Corp Recent Headline News
Daiichi Sankyo and Ambit Announce Results of Tender Offer
PR Newswire - Mon Nov 10, 6:37PM CST
Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) (TSE: 4568) and Ambit Biosciences Corporation (hereinafter, Ambit Biosciences) (NASDAQ: AMBI) today announced the results of Daiichi Sankyo's tender offer to purchase all of the outstanding shares of Ambit Biosciences' common stock for $15.00 per share plus one non-transferable contingent value right per share, which will entitle the holder thereof to a maximum payment of $4.50 upon the achievement of certain commercialization related milestones relating to quizartinib. The tender offer is being effected by Daiichi Sankyo's subsidiary, Charge Acquisition Corp.
AMBI: 15.60 (+0.26)
Ambit Announces Expiration of Hart-Scott-Rodino Waiting Period
PR Newswire - Tue Oct 28, 5:30PM CDT
Ambit Biosciences Corporation (hereinafter, Ambit Biosciences) (NASDAQ: AMBI) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR"
in connection with Daiichi Sankyo's previously announced tender offer for all of the outstanding common stock of Ambit Biosciences (hereinafter, the Tender Offer).
AMBI: 15.60 (+0.26)
Ciclofilin Pharmaceuticals Appoints Stephen F. Keane as Senior VP of Corporate Development
GlobeNewswire - Mon Oct 27, 10:07AM CDT
Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company", a developer of broad spectrum antiviral medications, announced today the appointment of Stephen F. Keane as Senior Vice President of Corporate Development. In this role, Mr. Keane will be responsible for structuring, negotiating and executing successful strategic alliances and co-development agreements, as well as providing general corporate development leadership to the Company.
MRK: 59.39 (+0.58), DNDN: 0.19 (+0.01), AMBI: 15.60 (+0.26)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Ambit Biosciences Corporation of Class Action Challenging the Fairness of the Sale of the Company to Daiichi Sankyo Company, Ltd. -- AMBI
GlobeNewswire - Mon Oct 20, 9:29AM CDT
Levi & Korsinsky notifies investors of Ambit Biosciences Corporation ("Ambit" or "the Company" (Nasdaq:AMBI) of claims of breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Daiichi Sankyo Company, Ltd. A complaint was filed in Delaware state court.
AMBI: 15.60 (+0.26)
Announcement Regarding Submission of Tender Offer for Shares in Ambit Biosciences Corporation
PR Newswire - Tue Oct 14, 3:43PM CDT
On Friday October 10, U.S. Eastern Time, Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) (TSE: 4568), through its wholly-owned U.S. subsidiary, Charge Acquisition Corp., launched a tender offer to acquire the outstanding common stock of Ambit Biosciences Corporation (hereinafter, Ambit Biosciences) (NASDAQ: AMBI) for $15.00 per share plus one non-transferable contingent value right per share that will entitle the holder thereof to a maximum payment of $4.50 upon the achievement of certain commercialization related milestones regarding quizartinib (hereinafter, the Tender Offer). Failing any extension to the offer period, the offer is due to expire at 5:00 P.M. U.S. Eastern Time on November 10, 2014.
AMBI: 15.60 (+0.26)
SHAREHOLDER ALERT - The Law Offices of Vincent Wong Investigates the Board of Directors of Ambit Biosciences Corporation in Connection With the Sale of the Company to Daiichi Sankyo Company, Ltd.
Business Wire - Tue Oct 14, 9:16AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Ambit Biosciences Corporation (NasdaqGM:AMBI) ("Ambit Biosciences" in connection with the sale of the Company to Daiichi Sankyo Company, Ltd.
AMBI: 15.60 (+0.26)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Ambit Biosciences Corporation in Connection with the Sale of the Company
Business Wire - Fri Oct 10, 8:35PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Ambit Biosciences Corporation ("Ambit" or the "Company" (Nasdaq: AMBI) relating to the proposed acquisition by Daiichi Sankyo Company, Ltd.
AMBI: 15.60 (+0.26)
Lifshitz & Miller Law Firm Announces Investigation of AcelRx Pharmaceuticals, Inc., Ambit Biosciences, Athlon Energy Inc., LipoScience, Inc., Simplicity Bancorp, Inc., and TIBCO Software Inc.
PR Newswire - Tue Oct 07, 5:31PM CDT
AcelRx Pharmaceuticals, Inc.
ACRX: 6.80 (+0.77), ATHL: 58.43 (+0.04), LPDX: 5.23 (+0.01), TIBX: 23.67 (+0.01), AMBI: 15.60 (+0.26), SMPL: 16.75 (unch)
SHAREHOLDER ALERT - The Law Offices of Vincent Wong Investigates the Board of Directors of Ambit Biosciences Corporation in Connection With the Sale of the Company to Daiichi Sankyo Company, Ltd. - AMBI
PR Newswire - Tue Oct 07, 12:05PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Ambit Biosciences Corporation (NasdaqGM: AMBI) ("Ambit Biosciences" in connection with the sale of the Company to Daiichi Sankyo Company, Ltd.
AMBI: 15.60 (+0.26)
It's True, Small-Cap Biotech Stocks Are Acting Badly These Days
at The Street - Tue Oct 07, 10:39AM CDT
For the past three months, small-cap biotech stocks are underperforming the broader market.
MNOV: 3.09 (+0.05), ESPR: 26.64 (+0.81), ADHD: 3.65 (-0.02), SNSS: 1.55 (-0.15), AMBI: 15.60 (+0.26)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Ambit Biosciences Corporation And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Mon Oct 06, 3:58PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Ambit Biosciences Corporation ("Ambit" or the "Company" (Nasdaq: AMBI) relating to the proposed buyout of the Company by Daiichi Sankyo Company, Ltd. ("Daiichi Sankyo".
AMBI: 15.60 (+0.26)
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Ambit Biosciences Corporation Concerning the Fairness of the Sale of the Company to Daiichi Sankyo Company, Ltd.
Business Wire - Wed Oct 01, 3:29PM CDT
Levi & Korsinsky is investigating the Board of Directors of Ambit Biosciences Corporation ("Ambit" or "the Company" (NasdaqGM: AMBI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Daiichi Sankyo Company, Ltd.
AMBI: 15.60 (+0.26)
Ambit Biosciences Corporation Stockholders Encouraged to Contact Securities Law Firm about Takeover
PR Newswire - Wed Oct 01, 2:23PM CDT
Securities lawyers at Dunnam & Dunnam are investigating the board of Ambit Biosciences Corporation (NASDAQ: AMBI) in connection with a buyout for only $15 per share. Concerned AMBI investors are encouraged to contact attorney Hamilton Lindley by clicking here.
AMBI: 15.60 (+0.26)
Ryan & Maniskas, LLP Announces Investigation of Ambit Biosciences Corporation
PR Newswire - Wed Oct 01, 10:48AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Ambit Biosciences Corporation ("Ambit" or the "Company" (NASDAQ: AMBI) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Daiichi Sankyo Company, Ltd. in a transaction valued at approximately $315 million.
AMBI: 15.60 (+0.26)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Ambit Biosciences Corporation in Connection with the Sale of the Company -AMBI
PR Newswire - Tue Sep 30, 5:35PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Ambit Biosciences Corporation ("Ambit" or the "Company" (Nasdaq: AMBI) relating to the proposed acquisition by Daiichi Sankyo Company, Ltd.
AMBI: 15.60 (+0.26)
AMBIT BIOSCIENCES CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Tue Sep 30, 4:50PM CDT
Rigrodsky & Long, P.A.:
AMBI: 15.60 (+0.26)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Ambit Biosciences Corporation Concerning its Proposed Sale to Daiichi Sankyo Company, Ltd.
Business Wire - Tue Sep 30, 4:15PM CDT
The Rosen Law Firm, P.A. announces that it is investigating the Board of Directors of Ambit Biosciences Corporation (NASDAQ:AMBI) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Ambit to maximize shareholder value before agreeing to be acquired by Daiichi Sankyo Company, Ltd.
AMBI: 15.60 (+0.26)
Nasdaq stocks posting largest percentage increases
AP - Tue Sep 30, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
CENX: 27.27 (-0.05), TRVN: 5.71 (-0.14), UNXL: 5.41 (-0.02), ICEL: 7.60 (-0.10), CLVS: 60.22 (+0.08), TIBX: 23.67 (+0.01), ORMP: 7.01 (-0.22), AMBI: 15.60 (+0.26), MOVE: 20.97 (-0.02), SAJA: 5.60 (-0.19)
AMBI Ambit Biosciences Corp Recent Headline News
Daiichi Sankyo and Ambit Announce Results of Tender Offer
PR Newswire - Mon Nov 10, 6:37PM CST
Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) (TSE: 4568) and Ambit Biosciences Corporation (hereinafter, Ambit Biosciences) (NASDAQ: AMBI) today announced the results of Daiichi Sankyo's tender offer to purchase all of the outstanding shares of Ambit Biosciences' common stock for $15.00 per share plus one non-transferable contingent value right per share, which will entitle the holder thereof to a maximum payment of $4.50 upon the achievement of certain commercialization related milestones relating to quizartinib. The tender offer is being effected by Daiichi Sankyo's subsidiary, Charge Acquisition Corp.
AMBI: 15.60 (+0.26)
Ambit Announces Expiration of Hart-Scott-Rodino Waiting Period
PR Newswire - Tue Oct 28, 5:30PM CDT
Ambit Biosciences Corporation (hereinafter, Ambit Biosciences) (NASDAQ: AMBI) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR"
in connection with Daiichi Sankyo's previously announced tender offer for all of the outstanding common stock of Ambit Biosciences (hereinafter, the Tender Offer). AMBI: 15.60 (+0.26)
Ciclofilin Pharmaceuticals Appoints Stephen F. Keane as Senior VP of Corporate Development
GlobeNewswire - Mon Oct 27, 10:07AM CDT
Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company"
, a developer of broad spectrum antiviral medications, announced today the appointment of Stephen F. Keane as Senior Vice President of Corporate Development. In this role, Mr. Keane will be responsible for structuring, negotiating and executing successful strategic alliances and co-development agreements, as well as providing general corporate development leadership to the Company. MRK: 59.39 (+0.58), DNDN: 0.19 (+0.01), AMBI: 15.60 (+0.26)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Ambit Biosciences Corporation of Class Action Challenging the Fairness of the Sale of the Company to Daiichi Sankyo Company, Ltd. -- AMBI
GlobeNewswire - Mon Oct 20, 9:29AM CDT
Levi & Korsinsky notifies investors of Ambit Biosciences Corporation ("Ambit" or "the Company"
(Nasdaq:AMBI) of claims of breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Daiichi Sankyo Company, Ltd. A complaint was filed in Delaware state court. AMBI: 15.60 (+0.26)
Announcement Regarding Submission of Tender Offer for Shares in Ambit Biosciences Corporation
PR Newswire - Tue Oct 14, 3:43PM CDT
On Friday October 10, U.S. Eastern Time, Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) (TSE: 4568), through its wholly-owned U.S. subsidiary, Charge Acquisition Corp., launched a tender offer to acquire the outstanding common stock of Ambit Biosciences Corporation (hereinafter, Ambit Biosciences) (NASDAQ: AMBI) for $15.00 per share plus one non-transferable contingent value right per share that will entitle the holder thereof to a maximum payment of $4.50 upon the achievement of certain commercialization related milestones regarding quizartinib (hereinafter, the Tender Offer). Failing any extension to the offer period, the offer is due to expire at 5:00 P.M. U.S. Eastern Time on November 10, 2014.
AMBI: 15.60 (+0.26)
SHAREHOLDER ALERT - The Law Offices of Vincent Wong Investigates the Board of Directors of Ambit Biosciences Corporation in Connection With the Sale of the Company to Daiichi Sankyo Company, Ltd.
Business Wire - Tue Oct 14, 9:16AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Ambit Biosciences Corporation (NasdaqGM:AMBI) ("Ambit Biosciences"
in connection with the sale of the Company to Daiichi Sankyo Company, Ltd. AMBI: 15.60 (+0.26)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Ambit Biosciences Corporation in Connection with the Sale of the Company
Business Wire - Fri Oct 10, 8:35PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Ambit Biosciences Corporation ("Ambit" or the "Company"
(Nasdaq: AMBI) relating to the proposed acquisition by Daiichi Sankyo Company, Ltd. AMBI: 15.60 (+0.26)
Lifshitz & Miller Law Firm Announces Investigation of AcelRx Pharmaceuticals, Inc., Ambit Biosciences, Athlon Energy Inc., LipoScience, Inc., Simplicity Bancorp, Inc., and TIBCO Software Inc.
PR Newswire - Tue Oct 07, 5:31PM CDT
AcelRx Pharmaceuticals, Inc.
ACRX: 6.80 (+0.77), ATHL: 58.43 (+0.04), LPDX: 5.23 (+0.01), TIBX: 23.67 (+0.01), AMBI: 15.60 (+0.26), SMPL: 16.75 (unch)
SHAREHOLDER ALERT - The Law Offices of Vincent Wong Investigates the Board of Directors of Ambit Biosciences Corporation in Connection With the Sale of the Company to Daiichi Sankyo Company, Ltd. - AMBI
PR Newswire - Tue Oct 07, 12:05PM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Ambit Biosciences Corporation (NasdaqGM: AMBI) ("Ambit Biosciences"
in connection with the sale of the Company to Daiichi Sankyo Company, Ltd. AMBI: 15.60 (+0.26)
It's True, Small-Cap Biotech Stocks Are Acting Badly These Days
at The Street - Tue Oct 07, 10:39AM CDT
For the past three months, small-cap biotech stocks are underperforming the broader market.
MNOV: 3.09 (+0.05), ESPR: 26.64 (+0.81), ADHD: 3.65 (-0.02), SNSS: 1.55 (-0.15), AMBI: 15.60 (+0.26)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Ambit Biosciences Corporation And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Mon Oct 06, 3:58PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Ambit Biosciences Corporation ("Ambit" or the "Company"
(Nasdaq: AMBI) relating to the proposed buyout of the Company by Daiichi Sankyo Company, Ltd. ("Daiichi Sankyo". AMBI: 15.60 (+0.26)
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Ambit Biosciences Corporation Concerning the Fairness of the Sale of the Company to Daiichi Sankyo Company, Ltd.
Business Wire - Wed Oct 01, 3:29PM CDT
Levi & Korsinsky is investigating the Board of Directors of Ambit Biosciences Corporation ("Ambit" or "the Company"
(NasdaqGM: AMBI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Daiichi Sankyo Company, Ltd. AMBI: 15.60 (+0.26)
Ambit Biosciences Corporation Stockholders Encouraged to Contact Securities Law Firm about Takeover
PR Newswire - Wed Oct 01, 2:23PM CDT
Securities lawyers at Dunnam & Dunnam are investigating the board of Ambit Biosciences Corporation (NASDAQ: AMBI) in connection with a buyout for only $15 per share. Concerned AMBI investors are encouraged to contact attorney Hamilton Lindley by clicking here.
AMBI: 15.60 (+0.26)
Ryan & Maniskas, LLP Announces Investigation of Ambit Biosciences Corporation
PR Newswire - Wed Oct 01, 10:48AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Ambit Biosciences Corporation ("Ambit" or the "Company"
(NASDAQ: AMBI) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Daiichi Sankyo Company, Ltd. in a transaction valued at approximately $315 million. AMBI: 15.60 (+0.26)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Ambit Biosciences Corporation in Connection with the Sale of the Company -AMBI
PR Newswire - Tue Sep 30, 5:35PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Ambit Biosciences Corporation ("Ambit" or the "Company"
(Nasdaq: AMBI) relating to the proposed acquisition by Daiichi Sankyo Company, Ltd. AMBI: 15.60 (+0.26)
AMBIT BIOSCIENCES CORPORATION SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Tue Sep 30, 4:50PM CDT
Rigrodsky & Long, P.A.:
AMBI: 15.60 (+0.26)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Ambit Biosciences Corporation Concerning its Proposed Sale to Daiichi Sankyo Company, Ltd.
Business Wire - Tue Sep 30, 4:15PM CDT
The Rosen Law Firm, P.A. announces that it is investigating the Board of Directors of Ambit Biosciences Corporation (NASDAQ:AMBI) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop Ambit to maximize shareholder value before agreeing to be acquired by Daiichi Sankyo Company, Ltd.
AMBI: 15.60 (+0.26)
Nasdaq stocks posting largest percentage increases
AP - Tue Sep 30, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
CENX: 27.27 (-0.05), TRVN: 5.71 (-0.14), UNXL: 5.41 (-0.02), ICEL: 7.60 (-0.10), CLVS: 60.22 (+0.08), TIBX: 23.67 (+0.01), ORMP: 7.01 (-0.22), AMBI: 15.60 (+0.26), MOVE: 20.97 (-0.02), SAJA: 5.60 (-0.19)
(0)
(0)